



## **INGENUITY'S IPA WINS BEST IN SHOW NEW PRODUCT AWARD AT BIO-IT WORLD CONFERENCE**

### ***Industry Leaders and Life Sciences Community Recognize IPA 5.0 for New Biomarker and Toxicology Innovations***

**Redwood City, CA – May 8, 2007** – Ingenuity Systems, the leading provider of solutions for the exploration, interpretation, and analysis of life science information, today announced that its life sciences knowledge solution, Ingenuity Pathways Analysis 5.0, won the “Best in Show” award at CHI’s Bio-IT World conference and expo held in Boston last week. IPA was chosen as the winner in the Life Science Software & Informatics category, which was judged by Bio-IT World magazine editors and highly regarded industry experts, whose criteria included technical merit, functionality, and innovation.

“We are delighted to have won this award,” stated Arthur Okamoto, Senior Product Manager at Ingenuity. “It is great recognition of IPA-Biomarker™ and IPA-Tox™, the new capabilities within the IPA application that enable researchers to mechanistically connect biomarkers to pathways of disease and drug response, and elucidate toxic effects not revealed by traditional methods. IPA is consistently used by researchers because it enables them to generate testable hypotheses, evaluate therapeutic strategies, and assess toxicity and safety in a straightforward and reliable manner.”

“A key distinction between IPA 5.0 and other offerings is the unrivaled breadth, depth, and consistency of the content contained within the solution”, commented Ramon Felciano, Chief Technology Officer of Ingenuity Systems. “When developing IPA 5.0, we expanded and updated the expert-extracted content to include new knowledge about diseases, exogenous and endogenous chemicals, and drugs and clinical candidates. We are pleased by this recognition of IPA 5.0, which is a testament to our ongoing commitment to support our customers and their research efforts.”

IPA is a software and content solution that provides unique insights and understanding of complex biological and chemical systems at the core of life science research. IPA is deployed in all major pharmaceutical companies and at hundreds of biotechnology companies and academic institutions globally. IPA supports analysis of data from all experimental platforms and is used at all stages of the drug discovery and development process, including target identification and validation, identification of biomarkers, predictive toxicology, and pharmacogenomics.

Trials of Ingenuity Pathways Analysis 5.0 are currently being offered at <http://www.ingenuity.com/trial>. For more information about Ingenuity Pathways Analysis 5.0, please email [sales@ingenuity.com](mailto:sales@ingenuity.com) or go to [www.ingenuity.com](http://www.ingenuity.com).

### **About Ingenuity Systems®**

Ingenuity enables researchers to model, analyze, and understand complex biological and chemical systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for life scientists and bioinformaticians, and enterprise knowledge management infrastructure, content, and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in

Redwood City, California, with offices in Germany, Switzerland, France, the United Kingdom, and Japan. [www.ingenuity.com](http://www.ingenuity.com).

**Contact:**

Heidi Bullock  
Director, Marketing  
Ingenuity Systems  
650.381.5150

# # #